Business Context and Reporting Period
Company: MEDICINOVA INC (MNOV)
Filing Type: Form 8-K (Current Report)
Date of Report: August 31, 2026
Event: Termination of a Material Definitive Agreement (Standby Equity Purchase Agreement).
Key Financial Metrics
This filing does not report comprehensive financial statements (revenue, profit, cash flow, or margins). Specific financial data related to the terminated agreement includes:
- Total SEPA Capacity: $30.0 million.
- Shares Issued Under SEPA: 175,000 shares.
- Price Range: $1.39 to $1.40 per share.
- Total Proceeds Received: $0.2 million.
- Outstanding Borrowings/Notices at Termination: None.
- Termination Fees: None due by either party.
Material Changes
The Company terminated its Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. ("Yorkville"), originally dated July 30, 2025. The termination notice was delivered on August 31, 2026, and the termination becomes effective on September 8, 2026. This action closes the facility under which the Company had the right to issue up to $30.0 million of common stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the termination of the financing facility. The Company confirmed that at the time of termination, there were no outstanding obligations, advance notices, or shares pending issuance under the agreement.
Investor Verification Checklist
- Verify the effective date of the SEPA termination (September 8, 2026).
- Confirm the total capital raised under the SEPA was limited to $0.2 million against a $30.0 million capacity.
- Check for any subsequent filings regarding new financing arrangements to replace the terminated SEPA.
- Review the Company's current cash position in the most recent 10-Q or 10-K to assess liquidity post-termination.